Skip to main content

Advertisement

Table 1 Clinical data, imaging abnormalities, and SSTR 2 expression

From: Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with 68Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy

Clinical data Imaging abnormalities SSTR 2
Pt no Age/sex Stage Previous therapy Gr Dg PFS (months) OS (months) Follow-up (months) V T1-Gad (cm 3 ) DOTA SUVmax BP C H L
1 49/F Primary   III A    29.4 0.57 TOC 0.79 −0.26 0 2 B
2 62/F Primary   III A    14.4 1.71 NOC 1.22b NA 0 2 B
3 44/F Primary   III A    21.0 0 NOC c 1 3 B
4 49/M Primary   III A    13.0 0 NOC 3 3 C
5 57/F Primary   III A 10.4   12.5 0.16 NOC 0.69 −0.47 0 0
6 18/M Primary   III A 10.9   11.8 0 NOC 0 3 B
7 49/F Primary   III A    10.7 0.81 NOC 0.69 d NA 1 3 C
8 32/F Primary   III A 8.4   13.8 0 X X X 0 1 C
9 54/F Primary   III O 13.6   27.7 0.03 NOC 3 3 B
10 60/M Primary   III OA    21.6 0 NOC 3 3 B
11 71/M Primary   IV GBMO 0 1.2   1.91 NOC 3.07 1.41 0 3 M
12 37/M Primary   IV GBMO    21.0 4.32 NOC 0.99 −0.62 3 3 B
13 35/F Primary   IV GBM 0 13.7   1.27 TOC 0.65 0.39 0 1 C
14 63/F Primary   IV GBM 24.0   24.1 12.2 NOC 2.21 0.98 0 0
15 62/F Primary   IV GBM 0 7.3   11.5 NOC 3.01 1.26 0 0
16 67/F Primary   IV GBM 0 4.4   14.8 NOC 1.62 0.36 0 1 B
17 70/M Primary   IV GBM 0 1.0   21.5 NOC 2.85 1.80 0 3 M
18 76/F Primary   IV GS 0 0.9   34.7 NOC 3.73 1.75 0 3 M
19 28/M Recurrent S III A 81.2   106.1 0 NOC 1 3 B
20 51/M Recurrent S, RT III O 60.9   253.7 0 NOC 3 3 B
21 42/F Recurrent S, S, RT, S III OA 24.3 99.5   0 NOC 3 3 C
22 46/M Recurrent S, RT, C III OA 39.0 100.4   28.2 NOC 5.68 3.33 1 1 C
23 42/F Recurrent S, CRT IV GBM 24.0 37.1   0.04 TOC 0.46 −0.34 0 3 B
24 68/F Recurrent S, CRT IV GBM 23.1 26.3   27.9 NOC 2.40 1.57 0 0
25 64/F Recurrent S, CRT IV GBM 34.2 38.2   12.8 NOC 2.70 1.07 0 3 B
26 42/F Recurrent S, CRT IV GBM 5.5 13.6   28.0 NOC 2.44 2.28 0 3 B
27 61/F Recurrent S, RT IV sGBM 16.1 21.3   2.59 NOC 1.98 0.64 0 2 C
28 57/M Recurrent S, CRT IV GBM 11.0 27.5   3.03a NOC 3.26 2.33 0 3 B
  1. Pt no, patient number; F, female; M, male; Gr, grade; Dg, diagnosis; A, astrocytoma; O, oligodendroglioma; OA, oligoastrocytoma; GBMO, glioblastoma with oligodendroglioma component; GBM, glioblastoma; sGBM, secondary GBM; GS, gliosarcoma; S, surgery; RT, radiotherapy; C, chemotherapy (temozolomide); CRT, chemoradiotherapy with adjuvant temozolomide; Dx, dexamethasone; TOC, 68Ga-DOTATOC; NOC, 68Ga-DOTANOC; −, no tracer uptake; X, no PET performed; NA, not applicable; C, intensity of most common staining (0 to 3); H, highest staining intensity (0 to 3); L, location of staining; C, cytoplasmic; M, membranous; B, both. aNo MRI (cardiac pacemaker), tumor volume defined from contrast-enhanced CT; bstatic PET 28 to 58 min post-injection (mild claustrophobia); cdynamic PET discontinued at 53 min post-injection (dyspnea); ddynamic PET discontinued at 36 min post-injection (numbness of the arm).